Menu Close

Company

Management Team

Jed Hubbs, Ph.D., President and CEO

Jed Hubbs

Jed has recent experience leading an initiative to build a drug discovery program at Codexis, a world leader in pharmaceutical biocatalysis. Before Codexis, Jed was Head of Medicinal Chemistry at Satori Pharmaceuticals, a venture-backed company focused on discovering and developing new Alzheimer’s disease therapies. He began his industrial career as a medicinal chemist at the new Merck site in Boston. Jed has a Ph.D. in organic synthesis from UC Berkeley and completed a NIH postdoctoral fellowship at Harvard University. He is an author or inventor on over 30 peer-reviewed publications and patent applications.

Matthew Toczko, Ph.D., Secretary and COO

Matthew Toczko
Matthew is an expert in Chemistry, Manufacturing and Controls (CMC) with over 15 years of experience. Prior to co-founding Neurocycle Therapeutics, he spent most of his career working for GlaxoSmithKline in Research Triangle Park, NC. There he served as a CMC technical leader and managed the site's early-phase chemical development group. He has lead both formulation development and chemical development for multiple drug candidates from candidate selection through phase 2. He began his career in GlaxoSmithKline's chemical development group. Matthew holds a Ph.D. in organic chemistry from U.C. Berkeley.

Scientific Advisors

Hanns Ulrich Zeilhofer

Hanns Ulrich Zeilhofer, M.D.

Dr. Zeilhofer is professor of Pharmacology at the University of Zurich and at the Swiss Federal Institute of Technology (ETH) Zurich. He received a Medical degree from the University of Erlangen-Nürnberg and is board-certified Clinical Pharmacologist. He has more than 20 years experience in neuropharmacology and pain research and is an author of more than 90 original research articles and of three patent applications.

Photo copyright: University of Zurich

John Atack

John Atack, Ph.D.

Dr. Atack is currently Sêr Cymru Professor of Translational Drug Discovery and Director of the newly-formed (summer 2017) Medicines Discovery Institute (MDI) at Cardiff University where he has already built a multidisciplinary team of around 35 biologists and chemists.

Prior to pursuing drug discovery in an academic environment, Prof. Atack gained extensive (>20 years) experience in neuroscience drug discovery initially with Merck & Co. in Harlow, UK (1989-2006) and then (2006-2012) with Janssen Pharmaceutical, where he was Head of Neuroscience Biology initially in San Diego and thereafter in Beerse, Belgium. He has worked on enzyme, ion channel and GPCR targets that cover a range of CNS disorders including Alzheimer’s disease, Parkinson’s disease, schizophrenia, anxiety, depression, cognitive impairment and addiction. He has over 160 publications and a proven track record of leading projects all the way from Target Identification/Target Validation through to clinical development and Phase 2a Proof-of-Concept and has been a major contributor for 15 compounds that have entered development of which 8 have progressed into clinical studies.

Sonja Ständer

Sonja Ständer, M.D.

Sonja Ständer is a Professor for Dermatology and Neurodermatology at the University Hospital of Münster’s Department of Dermatology and head of the Interdisciplinary Center for Chronic Pruritus (KCP) in Germany. She studied dermatology at universities in Münster and Vienna, and trained in dermatopathology at the Ackerman Academy in New York. In 2002, she founded the first outpatient clinic in Germany dedicated to patients suffering from pruritus. She is a former president and vice president of the International Forum for the Study of Itch (IFSI). She has remained head of an international special interest group developing tools used for measuring chronic pruritus for several years. She currently focuses her work primarily on clinical, experimental and translational pruritus research.